These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25768997)

  • 1. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):15-8. PubMed ID: 25768997
    [No Abstract]   [Full Text] [Related]  

  • 2. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
    Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
    Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
    Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
    Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
    Phillips T; Brunvand M; Chen AI; Essell J; Chiappella A; Diefenbach C; Cheng J; Ramies D; Hirata J; Morschhauser F; Flinn IW
    Am J Hematol; 2022 Jan; 97(1):E24-E27. PubMed ID: 34731510
    [No Abstract]   [Full Text] [Related]  

  • 6. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
    Amaya ML; Jimeno A; Kamdar M
    Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
    Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
    Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
    J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
    Eslami M; Mehrabi M; Payandeh M; Saba F
    PLoS One; 2024; 19(8):e0308247. PubMed ID: 39088571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
    Choi Y; Diefenbach CS
    Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
    Varma G; Wang J; Diefenbach C
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
    Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D
    Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Shi R; Lu T; Ku G; Ding H; Saito T; Gibiansky L; Agarwal P; Li X; Jin JY; Girish S; Miles D; Li C; Lu D
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):347-359. PubMed ID: 32770353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
    Lasater EA; Amin DN; Bannerji R; Mali RS; Barrett K; Rys RN; Oeh J; Lin E; Sterne-Weiler T; Ingalla ER; Go M; Yu SF; Krem MM; Arthur C; Hahn U; Johnston A; Karur V; Khan N; Marlton P; Phillips T; Gritti G; Seymour JF; Tani M; Yuen S; Martin S; Chang MT; Rose CM; Pham VC; Polson AG; Chang Y; Wever C; Johnson NA; Jiang Y; Hirata J; Sampath D; Musick L; Flowers CR; Wertz IE
    Am J Hematol; 2023 Mar; 98(3):449-463. PubMed ID: 36594167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
    Mehta A; Forero-Torres A
    Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
    Bourbon E; Salles G
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.
    Lu D; Gillespie WR; Girish S; Agarwal P; Li C; Hirata J; Chu YW; Kagedal M; Leon L; Maiya V; Jin JY
    CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):401-408. PubMed ID: 28544534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.